Literature DB >> 19716155

Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.

Francine Walker1, Laurent Abramowitz, Dalila Benabderrahmane, Xavier Duval, Véronique Descatoire, Dominique Hénin, Thérèse Lehy, Thomas Aparicio.   

Abstract

High prevalence of squamous anal lesions is linked to oncogenic human papillomavirus (HPV). Human immunodeficiency virus (HIV) promotes anal carcinogenesis. Epidermal growth factor receptor (EGFR), HER2/neu, c-Met, and vascular endothelial growth factor receptor-1 (VEGFR1) (tyrosine kinase growth factor receptors) are implicated in tumor progression, but little is known about their role in anal lesions. We investigated their expression and distribution in normal, dysplastic, and carcinomatous anal epithelium and then tried to analyze the effects on these variables of HPV and the HIV-positive status. Seventy-one HIV-positive and 47 HIV-negative patients were selected. We studied growth factor receptors, p16 and Ki67 expression, by in situ hybridization, fluorescent in situ hybridization (FISH) and chromogen in situ hybridization (CISH), immunocytochemistry, and morphological quantification in 226 lesions, either infected by HPV6 and 11 (31 condylomas acuminata) or infected with oncogenic HPVs (48 invasive cancers, 147 anal intraepithelial neoplasias). No HER2/neu was detected. Strong EGFR immunolabeling was not accompanied by gene amplification. The number and intensity of EGFR- and c-Met-immunoreactive cells increased significantly during lesion progression, highlighting the effects of oncogenic HPVs. EGFR, c-Met, VEGFR1, and p16 were coexpressed in 96% of invasive cancers. HIV-modified c-Met expression in condyloma acuminata (P < .008) and invasive cancers (P < .02). Strong HIV-related immunodeficiency and an absence of antiretroviral therapy increased c-Met and/or EGFR expression. HIV-positive anal cancers showed correlated c-Met and VEGFR1 (P < .003), strong p16 labeling, and an increased Ki67 proliferation. The finding that EGFR, c-Met, and VEGFR1 involved in carcinogenesis are well-represented and coexpressed in anal cancers, especially in HIV-positive population, suggests possible novel targeted treatments for anal diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716155     DOI: 10.1016/j.humpath.2009.05.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  41 in total

1.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

2.  Tissue-specific gene expression templates for accurate molecular characterization of the normal physiological states of multiple human tissues with implication in development and cancer studies.

Authors:  Pei-Ing Hwang; Huan-Bin Wu; Chin-Di Wang; Bai-Ling Lin; Cheng-Tao Chen; Shinsheng Yuan; Guani Wu; Ker-Chau Li
Journal:  BMC Genomics       Date:  2011-09-01       Impact factor: 3.969

Review 3.  Colorectal carcinogenesis--update and perspectives.

Authors:  Hans Raskov; Hans-Christian Pommergaard; Jakob Burcharth; Jacob Rosenberg
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  HIV- positive anal cancer: an update for the clinician.

Authors:  Savita V Dandapani; Michael Eaton; Charles R Thomas; Paul G Pagnini
Journal:  J Gastrointest Oncol       Date:  2010-09

Review 5.  Anal cancer treatment: current status and future perspectives.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Pamela Abdayem; Joelle Antoun; Dolly Nasr
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Selective Inhibition of STAT3 Phosphorylation Using a Nuclear-Targeted Kinase Inhibitor.

Authors:  Matthew D Bartolowits; Wells Brown; Remah Ali; Anthony M Pedley; Qingshou Chen; Kyle E Harvey; Michael K Wendt; Vincent Jo Davisson
Journal:  ACS Chem Biol       Date:  2017-08-18       Impact factor: 5.100

Review 7.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

8.  Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

Authors:  Nancy Van Damme; Philippe Deron; Nadine Van Roy; Pieter Demetter; Alain Bols; Jo Van Dorpe; Filip Baert; Jean-Luc Van Laethem; Franki Speleman; Patrick Pauwels; Marc Peeters
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

Review 9.  Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Authors:  Aaron M Gruver; Ziad Peerwani; Raymond R Tubbs
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

10.  Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation.

Authors:  Guoqing Qian; Dongsheng Wang; Kelly R Magliocca; Zhongliang Hu; Sreenivas Nannapaneni; Sungjin Kim; Zhengjia Chen; Shi-Yong Sun; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Eur J Cancer       Date:  2016-07-22       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.